FDA Avastin Breast Cancer Decision Doesn’t Impact Colorectal Cancer Treatment

Although FDA Commissioner Margaret Hamburg announced a final decision on November 18 to drop breast cancer from the Avastin label, metastatic colorectal cancer continues to be an approved use.

The Avastin® (bevacizumab) label includes the following approved indication:

Metastatic colorectal cancer, with intravenous 5-fluorouracil–based chemotherapy for first- or second-line treatment.

It is important to know that there is currently no approval or evidence for using Avastin alone or in early stage colon or rectal cancer.

Share on LinkedInShare on Google+Pin on PinterestTweet about this on TwitterShare on FacebookEmail this to someone

Related posts

*

*


7 − six =

Top